Your Guide to Peptide Research

A small molecule NNMT inhibitor studied for metabolic enhancement and fat cell reduction.

Abaloparatide (Tymlos) is a synthetic 34-amino-acid analog of parathyroid hormone-related protein, PTHrP(1-34), engineered to bind the PTH1 receptor with a strong preference for its transient RG conformation rather than the long-lived R0 conformation favored by teriparatide. That receptor bias produces a shorter burst of signaling per injection - enough to drive osteoblast activity, but short enough to limit the bone resorption and calcium mobilization that follow a prolonged signal. In the 18-month Phase 3 ACTIVE trial in 2,463 postmenopausal women, abaloparatide 80 mcg daily reduced new morphometric vertebral fractures by 86% versus placebo, alongside significant reductions in nonvertebral, major osteoporotic and clinical fractures. The FDA approved Tymlos in April 2017; in December 2021 the osteosarcoma boxed warning and the two-year cumulative lifetime limit were both removed from the label.

An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection.

A new class of antimicrobial peptides discovered and optimized using artificial intelligence platforms, with over 79 active compounds identified from a catalog of 863,498 AI-predicted sequences showing efficacy against multidrug-resistant pathogens.

An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback.

A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance.

Avacopan (Tavneos, CCX168) is the first oral C5a receptor (C5aR1/CD88) antagonist, FDA-approved as an add-on in severe ANCA-associated vasculitis. Here is how it blocks neutrophil-driving C5a, what the Phase 3 ADVOCATE trial showed, and why its real promise is getting patients off high-dose steroids.

AstraZeneca/Alexion's Voydeya (danicopan, ALXN2040) is the first approved oral factor D inhibitor - a pill added on top of a C5 inhibitor to shut down the alternative complement pathway's amplification loop and treat the extravascular hemolysis that eculizumab and ravulizumab leave running in PNH. Here is how factor D inhibition works, what the Phase 3 ALPHA trial showed, and how it compares with iptacopan and pegcetacoplan.

Novartis's Fabhalta (iptacopan, LNP023) is the first approved oral factor B inhibitor - a pill that clamps the alternative complement pathway at its source. It is now FDA-approved across three rare diseases: PNH, primary IgA nephropathy, and C3 glomerulopathy. In July 2026 it became the first complement inhibitor shown to slow kidney function decline in IgAN, cutting the annual rate of eGFR loss by about 48% versus placebo in APPLAUSE-IgAN.